ZGNX Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 01:00):

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States...

Stats
Tagesvolumen	11.25M
Durchschnittsvolumen	3.10M
Marktkapitalisierung	0.00
EPS	$-0.980 ( 2022-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.603 (2.26%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-07	Breitmeyer James B	Sell	1 250	Common Stock
2022-03-07	Breitmeyer James B	Sell	9 375	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	6 250	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	9 000	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 446 833 \| Sell: 2 096 567

Volumen Korrelation

Lang: 0.49 (neutral)

Kurz: 0.91 (very strong)

Signal:(77.726) Expect same movement, but be aware

Zogenix Inc Korrelation

10 Am meisten positiv korreliert
BRACU	0.97
ATRS	0.969
ATCX	0.967
XLRN	0.957
CTSO	0.955
EYEN	0.952
ARAY	0.947
NVCN	0.946
ALGN	0.945
FOCS	0.945

10 Am meisten negativ korreliert
NAKD	-0.948
TRIT	-0.935
AHPI	-0.931
AMRB	-0.922
GRPH	-0.922
GRIN	-0.909
PROC	-0.907
CHKEL	-0.905
TUEM	-0.904
LAWS	-0.902

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Zogenix Inc Korrelation - Währung/Rohstoff

0.16
( neutral )

0.68
( moderate )

0.64
( weak )

0.40
( neutral )

0.56
( weak )

-0.18
( neutral )

Zogenix Inc Finanzdaten

Annual	2021
Umsatz:	$81.69M
Bruttogewinn:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2021
Umsatz:	$81.69M
Bruttogewinn:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2020
Umsatz:	$13.64M
Bruttogewinn:	$13.10M (96.03 %)
EPS:	$-3.90

FY	2019
Umsatz:	$3.65M
Bruttogewinn:	$3.65M (100.00 %)
EPS:	$-9.74

Financial Reports:

No articles found.

Zogenix Inc

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.